Glargine metabolism has been studied in insulin-treated people with type 2 diabetes (T2D) at usual glargine doses of 0.4-0.8 units/kg/day (1, 2) . In some obese subjects with insulin-resistant T2D, higher basal insulin doses are needed, and the question of safety of glargine (3) is therefore still relevant. Epidemiological studies indicate that the risk of cancer is especially elevated in obese individuals with insulin-resistant diabetes requiring high insulin doses (4). Unmodified insulin glargine has been suggested to confer a higher risk of cancer (3), but prior studies have shown that, at usual doses, an active metabolite (M1) with actions similar to human insulin is the main circulating molecule after glargine injection (1, 2) .
The aim of the current study was to establish the plasma levels of insulin glargine (M0) and its metabolites M1 and M2 (1, 2) in subjects with T2D treated long-term with glargine dose $1.2 units/kg/day.
Blood samples of 10 subjects with T2D (male/female 5/5, age 56 6 10 years, BMI 37.9 6 7.9 kg/m 2 , A1C 8.9 6 1.3% [74 6 15 mmol/mol], diabetes duration 19 6 10 years, glargine dose 162 6 63 units/day [1.49 6 0.28 units/kg/day], prandial insulin dose 74 6 37 units/day) (mean 6 SD) were drawn in the fasting state, 12 6 1 h after last subcutaneous glargine injection and processed as previously described (1,2). Plasma was stored at 2808C and analyzed within 6 months (to prevent possible deterioration) for M0, M1, and M2 (liquid chromatographytandem mass spectrometry method, sensitivity 0.2 ng/mL for each analyte, ;34 pmol/L) (for method details see ref.
2).
Plasma M0 was 31 6 41.6 pmol/L, whereas M1 concentration was 457 6 337 pmol/L in the 10 subjects studied. M0 represented 4.1 6 6.1% and M1 represented 95.9 6 6.1% of total plasma insulin. M2 was not detected in any of the subjects studied.
Plasma M0 was detected in only 4 out of the 10 subjects, whereas M1 was detectable in all 10 subjects (Fig. 1) . In the 4 subjects in whom it was detectable, M0 had a concentration of 78 6 19 pmol/L (subject 1, 53 pmol/L; subject 3, 96 pmol/L; subject 6, 89 pmol/L; subject 10, 74 pmol/L) ( Fig. 1) and represented 10.4 6 5.2% of the total circulating insulin. M1 had a concentration of 772 6 321 pmol/L in the 4 subjects in whom M0 was detected and represented 89.6 6 5.2% of total circulating insulin.
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